Elahere® (mirvetuximab soravtansine-gynx)
for Ovarian Cancer
Elahere (mirvetuximab soravtansine-gynx) is an injectable antibody-drug conjugate used to treat adults with FRα-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer, after 1-3 prior systemic treatments. It targets FRα, a protein found on ovarian cancer cells. Once bound, the drug is internalized, releasing DM4, a microtubule inhibitor that disrupts the cell, causing it to collapse and die.
